The Flow Cytometry Core Facility (FCCP) provides state-of-the-art flow cytometry services to researchers at the Cancer Center. Extensive user support is provided, consisting of daily instrument startup, maintenance and quality control;easy and reliable online scheduling systems;extensive training options;a site license for FlowJo analysis software;one-on-one consultations between individual researchers and Core Facility staff. These services include Operator-Assisted analysis on FACSCalibur and CyAn, Operator-Assisted cell sorting on two Aria and two MoFlo cell sorters, as well as User-Operated analysis on FACSCalibur, LSR II and Fortessa and User-Operated cell sorting on two Aria cell sorters. The combination of equipment and user support offers researchers opportunity to integrate flow cytometric analysis and cell sorting into their research projects. FCCP provides easy access to purified cell populations and to analysis of cellular subsets and processes, essential elements of many modern cell biology research projects. The presence of FCCP therefore plays an important role in the Center's capability to increase our knowledge of the processes that give rise to cancer, and to improve cancer diagnosis and therapy. The services and collaborative work provided by the FCCF has supported the research of 111 investigators in the past year. During the past grant period the work of the Core has contributed to 450 publications of researchers from 8 research programs. For example, the Flow Core was essential in helping the Rudensky lab demonstrate that regulatory T(Treg) cells integrate environmental cues that suppress particular types of Inflammation. These studies showed that Treg cell-mediated suppression of Th17-driven pathology is facilitated by activation of STAT3 downstream of interleukin 10-R (IL-1 OR) engagement of interleukin 10 (IL-10). This study demonstrated that IL-10 endows Treg cells with the ability to suppress pathogenic Thi7 cell responses. For these studies the Core provided expert flow analysis of STAT3 staining and cell sorting of Fox3-YFPT+ and Fox3-TFP- cells.

Public Health Relevance

The FCCF provides essential services and instrumentation that enable Center investigators to simultaneously analyze multiple characteristics on large numbers of cells and to Isolate highly purified populations of cells that have specific features.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-48
Application #
8933486
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2014-01-01
Project End
2018-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
48
Fiscal Year
2014
Total Cost
$362,498
Indirect Cost
$158,504
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Antonescu, Cristina R; Agaram, Narasimhan P; Sung, Yun-Shao et al. (2018) A Distinct Malignant Epithelioid Neoplasm With GLI1 Gene Rearrangements, Frequent S100 Protein Expression, and Metastatic Potential: Expanding the Spectrum of Pathologic Entities With ACTB/MALAT1/PTCH1-GLI1 Fusions. Am J Surg Pathol 42:553-560
Baumann, Michael H; Majumdar, Susruta; Le Rouzic, Valerie et al. (2018) Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. Neuropharmacology 134:101-107
Escalon, Joanna G; Harrington, Kate A; Plodkowski, Andrew J et al. (2018) Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography? J Comput Assist Tomogr 42:601-606
Rosen, Lauren E; Karrison, Theodore; Ananthanarayanan, Vijayalakshmi et al. (2018) Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol 31:598-606
Argani, Pedram; Pawel, Bruce; Szabo, Sara et al. (2018) Diffuse Strong BCOR Immunoreactivity Is a Sensitive and Specific Marker for Clear Cell Sarcoma of the Kidney (CCSK) in Pediatric Renal Neoplasia. Am J Surg Pathol 42:1128-1131
Lambertini, Matteo; Campbell, Christine; Bines, José et al. (2018) Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. J Natl Cancer Inst :
Intlekofer, Andrew M; Joffe, Erel; Batlevi, Connie L et al. (2018) Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer J 8:60
Wang, Hongmei; Deng, Jikui; Tang, Yi-Wei (2018) Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test. Expert Rev Mol Diagn 18:403-409
Tseng, Jill H; Aloisi, Alessia; Sonoda, Yukio et al. (2018) Long-Term Oncologic Outcomes of Uterine-Preserving Surgery in Young Women With Stage Ib1 Cervical Cancer. Int J Gynecol Cancer 28:1350-1359
Pronier, Elodie; Bowman, Robert L; Ahn, Jihae et al. (2018) Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. Blood 132:1265-1278

Showing the most recent 10 out of 8799 publications